Intellia Therapeutics Shares Fall After Q3 Revenue Misses Estimates

10:34 AM EST, 11/05/2026 (MT Newswires) -- Intellia Therapeutics (NTLA) shares were down 5% in early Thursday trading after it reported Q3 revenue that fell year on year and missed analyst estimates. The company a reported Q3 net loss Thursday of $0.91 per diluted share, narrower than a loss of $0.92 a year earlier. Analysts polled by FactSet expected a loss of $0.80. Revenue for the quarter ended Sept. 30 was $7.2 million, down from $13.8 million a year earlier. Analysts expected $9.7 million. Price: 11.56, Change: -0.76, Percent Change: -6.13